Key Mounjaro facts: what the medicine is, how it works, and what the evidence shows

Step 1: understand what Mounjaro actually is (and one thing it isn't)

Mounjaro is the brand name for tirzepatide, made by Eli Lilly and approved in the UK for weight management alongside a reduced-calorie diet and increased activity. Adults with a BMI of 30 or above qualify on that basis alone; adults with a BMI of 27 or above may qualify if they have at least one weight-related condition such as high blood pressure, high cholesterol, type 2 diabetes or obstructive sleep apnoea.

One misconception worth clearing up: Mounjaro is sometimes described online as a diabetes drug repurposed for weight loss. That framing misses something important. Tirzepatide holds two separate UK licences, one for type 2 diabetes and a distinct licence for weight management. The formulation, dose schedule and clinical trials for weight management are specific to that indication. It was developed for both purposes, not borrowed from one for the other.

You can read more about the broader clinical picture on our tirzepatide treatment overview, which covers the full evidence base. The NHS also publishes a straightforward patient-level summary at nhs.uk/medicines/tirzepatide, a useful first read before your consultation.

Step 2: understand the mechanism, why two receptors matter

Most GLP-1 medicines work on a single receptor pathway. Mounjaro is a dual GIP and GLP-1 receptor agonist, meaning it mimics two naturally occurring gut hormones simultaneously. GLP-1 slows how quickly the stomach empties and signals fullness to the brain. GIP adds a second layer of appetite regulation and may influence how the body handles fat metabolism.

In practice, this means appetite tends to fall noticeably, particularly during the first weeks after a dose increase. Many people find that portion sizes drop naturally rather than by deliberate effort. That does not mean the medicine does the work alone: the trial evidence was gathered alongside dietary and activity support, and prescribers at our clinical team always recommend treating the treatment as a tool rather than a standalone fix.

For people curious about less obvious physiological effects, there is emerging discussion around whether tirzepatide influences stress hormones, our page on whether Mounjaro affects cortisol levels sets out what the current evidence does and does not show.

Step 3: know the trial results and how to read them honestly

The headline figure from SURMOUNT-1 (the pivotal phase 3 trial, published in the New England Journal of Medicine) is an average body-weight reduction of around 20–21% over 72 weeks at the 15 mg dose. Some analyses of that dataset reached around 22.5%. Those numbers come from 2,539 adults without diabetes who received intensive lifestyle support alongside tirzepatide. If you want a fuller grounding before digesting those figures, our guide to the key facts about Mounjaro is a good place to start. Hedge them honestly: they are trial results under controlled conditions, not a personal forecast.

A more recent head-to-head comparison is also worth knowing about. In the SURMOUNT-5 trial (72 weeks, published in the New England Journal of Medicine in 2025), tirzepatide produced greater average weight reduction than semaglutide 2.4 mg in adults with obesity but without diabetes. That does not mean semaglutide is inferior for every individual, which treatment fits a person depends on their health history, tolerability and what their prescriber judges appropriate.

NICE assessed tirzepatide in its technology appraisal TA1026 and recommended it for NHS use under specific eligibility thresholds. Understanding those thresholds helps explain why private routes exist: many people who would benefit clinically do not yet meet the NHS phased-rollout criteria or prefer not to wait.

Step 4: understand the side-effect profile before you start

The most common side effects are gastrointestinal: nausea, constipation, diarrhoea, indigestion and burping. Injection-site reactions, fatigue and headache also appear in the trial data. These effects tend to be most noticeable in the first few days after starting or stepping up a dose, and they generally ease as the body adjusts over days to a couple of weeks.

There are a small number of serious side effects to be aware of. Acute pancreatitis is a known but infrequent risk; the MHRA issued guidance in January 2026 advising anyone on a GLP-1 medicine to seek urgent medical help for severe, persistent stomach pain that radiates to the back, with or without vomiting. Anyone with a personal or family history of medullary thyroid carcinoma, MEN2, pancreatitis or certain gastrointestinal conditions should discuss those details fully with a prescriber before starting.

Mounjaro is not recommended during pregnancy, breastfeeding or when trying to conceive. Women taking oral contraceptives should use an additional non-oral method for the first four weeks of treatment and for four weeks after each dose increase, because the pill's absorption may be reduced. Some people also notice changes in their appearance during treatment, and our page on the facial changes sometimes associated with Mounjaro explains what can happen and why. Our page covering Mounjaro treatment in full expands on these safety considerations, and the frequently asked questions section covers many of the practical queries our prescribers hear most often.

If you have questions about cost before deciding whether to consult, our overview of Eli Lilly's UK price changes explains the pricing context clearly, including what happened to list prices from September 2025 and what to expect from private providers.

When you feel ready, speak to our prescribers through a free consultation, reviewed the same day by a GPhC-registered Independent Prescriber, with no waiting list.